Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Deep Brain Stimulation Devices Market: By Product, By Type, By Application, and Region Forecast 2020-2031
Deep Brain Stimulation Devices Market size was valued at US$ 1,892.1 million in 2024 and is expected to reach US$ 4,236.3 million by 2031, growing at a significant CAGR of 10.6% from 2025-2031. Moreover, the U.S. Global Deep Brain Stimulation Devices Market is projected to grow significantly, reaching an estimated value of US$ 1,321.7 Million by 2031. The Deep Brain Stimulation Device is a medical implant that delivers electrical impulses to specific areas of the brain to help manage neurological disorders such as Parkinson’s disease, essential tremor, dystonia, epilepsy, and obsessive-compulsive disorder. The Deep Brain Stimulation (DBS) devices market is witnessing robust growth globally, fueled by key drivers such as the rising prevalence of neurological disorders like Parkinson’s disease, epilepsy, and dystonia. Technological innovations, especially adaptive DBS systems, personalized stimulation, significantly enhance treatment efficacy. A major trend shaping the market is the deepening integration of DBS devices with advanced computational platforms, AI algorithms, and remote monitoring systems, allowing clinicians to adjust therapies remotely and align with patient-specific symptom patterns.
Many opportunities lie in the development of closed-loop DBS systems that sense and respond to brain activity dynamically, offering improved patient outcomes with fewer side effects. Additionally, partnerships among companies, academic institutions, and government bodies are accelerating clinical trials and regulatory approvals. However, the market faces challenges including high initial treatment costs, limited insurance coverage in certain regions, and surgical risks that hinder adoption.
Based on the Product:
The dual-channel deep brain stimulator segment dominates the largest market share, owing to its increasing adoption by neurosurgeons, as it is highly effective in providing bilateral therapy and reducing patient tremors across multiple brain regions. Dual-channel devices offer more precise and personalized stimulation, enhancing therapeutic outcomes for complex neurological disorders.
The single-channel deep brain stimulator segment is expected to witness the fastest growth rate as it provides substantial therapeutic benefits at a more affordable price point, making DBS therapy accessible to a wider patient population.
Based on the type:
The subthalamic DBS (STN-DBS) segment held the largest market revenue share due to its proven efficacy in motor symptom control and widespread clinical acceptance. This type of DBS provides significant improvements in dyskinesia and motor fluctuations. The globus pallidus DBS segment is expected to witness the fastest compound annual growth rate driven by its increasing adoption as an alternative treatment for patients with Parkinson’s disease who do not respond adequately to subthalamic DBS or medication. This segment's growth is further supported by advancements in DBS technology and expanding clinical indications.
Based on the Application:
The Parkinson’s disease segment held the largest market revenue share, which is expected to be driven by the high global prevalence of the disease and the well-established efficacy of DBS as a significant treatment option for managing its motor symptoms. On June 4, 2025, Reuters reported that Morten Harket, the lead singer of iconic band A-ha, publicly disclosed his Parkinson’s disease diagnosis. The openness of a high-profile global figure undergoing brain surgery to manage symptoms has drawn extensive media coverage, shedding light on both the challenges and the treatments related to Parkinson’s. The Essential Tremor segment has a low market share, but it is anticipated to witness the fastest compound annual growth rate, fueled by increasing awareness and the high success rate of DBS in alleviating tremors, significantly improving patients' quality of life.
Study Period
2025-2031Base Year
2024CAGR
10.6%Largest Market
North-AmericaFastest Growing Market
Asia-Pacific
One of the key drivers of the deep brain stimulation devices market is the increasing global prevalence of neurological disorders such as Parkinson's disease, essential tremor, and dystonia, coupled with continuous technological advancements in neurostimulation devices, which is a significant driver for the heightened demand for deep brain stimulation solutions. For instance, in January 2025, Medtronic introduced its FDA-approved adaptive deep-brain stimulation (DBS) system in the Bay Area, a first for real-world treatment, moving beyond clinical trials. Unlike traditional DBS, which delivers constant stimulation, this “brain pacemaker” system senses neural activity in real time and adjusts stimulation accordingly. It shows the technical advancement in the neurostimulation device segment.
Furthermore, the growing acceptance of neurostimulation therapies and the desire for personalized treatment options are making DBS an integral component of neurological care, offering seamless integration with patient management protocols and multidisciplinary care teams.
A significant challenge restraining the deep brain stimulation devices market is the high initial capital investment, and integration complexity is also a major issue, which significantly hinders widespread adoption of this strategy. For instance, the high cost of DBS surgery and the implanted neurostimulator can be a barrier for many patients, particularly in regions with less comprehensive insurance coverage or lower disposable incomes. Addressing these financial concerns through favourable reimbursement policies, expanding insurance coverage, and developing more cost-effective device options is crucial for broadening patient access. Companies in the DBS market emphasize the long-term benefits and potential for reduced medication costs to justify the initial investment.
In addition, the inherent surgical risks associated with DBS, such as infection, haemorrhage, or device-related complications, can be a barrier to adoption for some patients and clinicians.
One of the most significant opportunities in the deep brain stimulation (DBS) market lies in the surge of R&D investments with advancing next-generation technologies. The major medical device companies are backed by government grants and academic partnerships, and are focusing heavily on developing closed-loop DBS systems, a system that enables devices to sense and respond to neural activity in real time. This adaptive approach allows for dynamic stimulation based on a patient’s brain signals, offering more precise treatment with fewer side effects. Innovations are also emerging in targeting technologies, including AI-powered navigation and high-resolution imaging, which improve electrode placement and overall surgical outcomes. Companies are exploring novel stimulation parameters to enhance efficacy, patient comfort, and battery life. Furthermore, collaborations between industry and institute ons are not only expediting regulatory pathways but also ensuring these devices are clinically robust. Altogether, these research-driven advancements are reshaping DBS therapy and expanding its potential applications in neurology.
A prominent trend shaping the deep brain stimulation devices market is the deepening integration with adaptive technology and advanced computational platforms. This fusion of technologies is significantly enhancing personalized therapy management, improving patient outcomes, and optimizing clinical workflows. For instance, next-generation DBS systems are incorporating advanced algorithms to analyse patient symptom patterns in real-time, allowing for adaptive stimulation that adjusts automatically based on movement or tremor fluctuations. Similarly, some devices enable secure, remote adjustments by clinicians, offering a more discreet and convenient solution for managing therapy without frequent clinic visits.
Along with this, the seamless integration of DBS systems with electronic health records (EHR) and remote monitoring platforms facilitates centralized control over various aspects of patient care. Through a single interface, clinicians can manage device settings alongside patient medical history, symptom diaries, and other health data, creating a unified and automated therapeutic experience.
Report Benchmarks |
Details |
Report Study Period |
2025-2031 |
Market Size in 2024 |
US$ 1,892.1 million |
Market Size in 2031 |
US$ 4,236.3 million |
Market CAGR |
10.6% |
By Product |
|
By Type |
|
By Application |
|
By Region |
|
According to a PBI Analyst, the Deep Brain Stimulation (DBS) devices market is primarily driven by the rising global prevalence of neurological disorders like Parkinson’s disease, essential tremor, and dystonia, along with ongoing technological innovations such as adaptive DBS systems that adjust stimulation in real time. A major trend shaping the market is the integration of advanced computational platforms and AI, enabling personalized, real-time therapy adjustments and remote device management, which enhances patient outcomes and clinical efficiency. Significant opportunities lie in expanding R&D efforts focusing on next-generation closed-loop DBS systems, AI-powered targeting technologies, and collaborations accelerating regulatory approvals.
However, market growth is restrained by high initial costs, surgical risks, and integration complexities, limiting accessibility, especially in regions with limited insurance coverage. Addressing these challenges through improved reimbursement policies and cost-effective devices will be critical for broader adoption. Overall, the DBS market is evolving rapidly with innovation-driven growth balanced by the need to overcome financial and clinical barriers.
Download Free Sample Report
The deep brain stimulation devices market size was valued at US$ 1,892.1 million in 2024 and is projected to grow at a CAGR of 10.6% from 2025-2031.
The market key players are: Medtronic Plc (U.S.) Boston Scientific Corporation (U.S.) Abbott Laboratories (U.S.) Aleva Neurotherapeutics SA (Switzerland) Soterix Medical Inc. (U.S.) Bioinduction Ltd. (U.K) St. Jude Medical Inc. (U.S.)
The rapidly growing demand for fast and convenient e-commerce order fulfilment, technological innovation, and integration of AI.
The deepening integration with adaptive technology, advanced computational platforms, seamless integration of DBS systems with electronic health records (EHR), and remote monitoring platforms.
Asia-Pacific is the fastest-growing region for market.
1.Executive Summary |
2.Global Deep Brain Stimulation Devices Market Introduction |
2.1.Global Deep Brain Stimulation Devices Market - Taxonomy |
2.2.Global Deep Brain Stimulation Devices Market - Definitions |
2.2.1.Product |
2.2.2.Type |
2.2.3.Application |
2.2.4.Region |
3.Global Deep Brain Stimulation Devices Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4.Global Deep Brain Stimulation Devices Market Analysis, 2020 - 2024 and Forecast 2025 - 2031 |
4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5.Global Deep Brain Stimulation Devices Market By Product, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
5.1. Single-channel deep brain stimulator |
5.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Dual-channel deep brain stimulator |
5.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
6.Global Deep Brain Stimulation Devices Market By Type, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
6.1. Subthalamic DBS |
6.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Globus pallidus DBS |
6.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Thalamic DBS |
6.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
6.4. Pedunculopontine nucleus DBS |
6.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.4.3. Market Opportunity Analysis |
7.Global Deep Brain Stimulation Devices Market By Application, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
7.1. E-commerce |
7.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Pain management |
7.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Epilepsy |
7.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
7.4. Essential tremor |
7.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.4.3. Market Opportunity Analysis |
7.5. Obsessive-compulsive disorder (OCD) |
7.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.5.3. Market Opportunity Analysis |
7.6. Depression |
7.6.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
7.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.6.3. Market Opportunity Analysis |
7.7. Dystonia |
7.7.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
7.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.7.3. Market Opportunity Analysis |
7.8. Parkinson’s disease |
7.8.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
7.8.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.8.3. Market Opportunity Analysis |
8.Global Deep Brain Stimulation Devices Market By Region, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
8.1. North America |
8.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Europe |
8.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Asia Pacific (APAC) |
8.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Middle East and Africa (MEA) |
8.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
8.5. Latin America |
8.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.5.3. Market Opportunity Analysis |
9.North America Deep Brain Stimulation Devices Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
9.1. Product Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.1.1.Single-channel deep brain stimulator |
9.1.2.Dual-channel deep brain stimulator |
9.2. Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.2.1.Subthalamic DBS |
9.2.2.Globus pallidus DBS |
9.2.3.Thalamic DBS |
9.2.4.Pedunculopontine nucleus DBS |
9.3. Application Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.3.1.E-commerce |
9.3.2.Pain management |
9.3.3.Epilepsy |
9.3.4.Essential tremor |
9.3.5.Obsessive-compulsive disorder (OCD) |
9.3.6.Depression |
9.3.7.Dystonia |
9.3.8.Parkinson’s disease |
9.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.4.1.United States of America (USA) |
9.4.2.Canada |
10.Europe Deep Brain Stimulation Devices Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
10.1. Product Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Single-channel deep brain stimulator |
10.1.2.Dual-channel deep brain stimulator |
10.2. Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Subthalamic DBS |
10.2.2.Globus pallidus DBS |
10.2.3.Thalamic DBS |
10.2.4.Pedunculopontine nucleus DBS |
10.3. Application Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.E-commerce |
10.3.2.Pain management |
10.3.3.Epilepsy |
10.3.4.Essential tremor |
10.3.5.Obsessive-compulsive disorder (OCD) |
10.3.6.Depression |
10.3.7.Dystonia |
10.3.8.Parkinson’s disease |
10.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.4.1.Germany |
10.4.2.France |
10.4.3.Italy |
10.4.4.United Kingdom (UK) |
10.4.5.Spain |
11.Asia Pacific (APAC) Deep Brain Stimulation Devices Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
11.1. Product Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Single-channel deep brain stimulator |
11.1.2.Dual-channel deep brain stimulator |
11.2. Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Subthalamic DBS |
11.2.2.Globus pallidus DBS |
11.2.3.Thalamic DBS |
11.2.4.Pedunculopontine nucleus DBS |
11.3. Application Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.E-commerce |
11.3.2.Pain management |
11.3.3.Epilepsy |
11.3.4.Essential tremor |
11.3.5.Obsessive-compulsive disorder (OCD) |
11.3.6.Depression |
11.3.7.Dystonia |
11.3.8.Parkinson’s disease |
11.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.4.1.China |
11.4.2.India |
11.4.3.Australia and New Zealand (ANZ) |
11.4.4.Japan |
11.4.5.Rest of APAC |
12.Middle East and Africa (MEA) Deep Brain Stimulation Devices Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
12.1. Product Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Single-channel deep brain stimulator |
12.1.2.Dual-channel deep brain stimulator |
12.2. Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Subthalamic DBS |
12.2.2.Globus pallidus DBS |
12.2.3.Thalamic DBS |
12.2.4.Pedunculopontine nucleus DBS |
12.3. Application Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.E-commerce |
12.3.2.Pain management |
12.3.3.Epilepsy |
12.3.4.Essential tremor |
12.3.5.Obsessive-compulsive disorder (OCD) |
12.3.6.Depression |
12.3.7.Dystonia |
12.3.8.Parkinson’s disease |
12.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.4.1.GCC Countries |
12.4.2.South Africa |
12.4.3.Rest of MEA |
13.Latin America Deep Brain Stimulation Devices Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
13.1. Product Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.1.1.Single-channel deep brain stimulator |
13.1.2.Dual-channel deep brain stimulator |
13.2. Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.2.1.Subthalamic DBS |
13.2.2.Globus pallidus DBS |
13.2.3.Thalamic DBS |
13.2.4.Pedunculopontine nucleus DBS |
13.3. Application Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.3.1.E-commerce |
13.3.2.Pain management |
13.3.3.Epilepsy |
13.3.4.Essential tremor |
13.3.5.Obsessive-compulsive disorder (OCD) |
13.3.6.Depression |
13.3.7.Dystonia |
13.3.8.Parkinson’s disease |
13.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.4.1.Brazil |
13.4.2.Mexico |
13.4.3.Rest of LA |
14. Competition Landscape |
14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
14.2.1.Abbott |
14.2.2.ALEVA NEUROTHERAPEUTICS |
14.2.3.Boston Scientific Corporation |
14.2.4.LivaNova PLC |
14.2.5.Medtronic |
14.2.6.Neuropace Inc. |
14.2.7.Nexstim Oy |
15. Research Methodology |
16. Appendix and Abbreviations |
Key Market Players